New drug combo trial targets stubborn blood cancer
NCT ID NCT04169737
Summary
This study is testing whether adding an immunotherapy drug (obinutuzumab) earlier to a two-drug combination (acalabrutinib + venetoclax) works better for people with chronic lymphocytic leukemia (CLL) that has returned or hasn't responded to previous treatments. The goal is to better control the cancer and reduce it to very low levels in the bone marrow. About 168 participants will be randomly assigned to receive either the two-drug combo alone or with the immunotherapy drug added early in treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.